Plasma von Willebrand Factor, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor, and Antithrombin III Levels in Behçet's Disease

References

• Kog Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behqt's Disease. J Rheumatol 1992; 19: 402–10
   PubMed Web of Science ®Google Scholar
• Adler O B, Rosenberger A. Vascular aspects of Behcet Disease. Ann Radial* 1984; 27: 371–5
   PubMedGoogle Scholar
• Aldalaan A, Albalaa S, Ali M A, Huraib S, Amin T, Almaziad A, et al. Budd-Chiari syndrome in association with Behget's Disease. J Rheumatol 1991; 18: 622–6
   PubMed Web of Science ®Google Scholar
• Yanci H, Pazarli H, Barnes C G, Tiiziin Y, Özyazgan Y, Silman A, et al. A controlled trial of Azathioprine in Behqet's syndrome. N Engl J Med 1990; 322: 281–5
   PubMed Web of Science ®Google Scholar
• Lie J T. Classification and immunodiagnosis of vasculitis. J Rheumatol 1988; 15: 728–32
   PubMed Web of Science ®Google Scholar
• Savage C OS, Cooke S P. The role of endothelium in systemic vasculitis. J Autoimmun 1993; 6: 23749
   Web of Science ®Google Scholar
• Cotran R S. Endothelial cells. Textbook of Rheumatology, W N Kelly, E D Harris, S Ruddy, C B Sledge. W. B. Saunders Company. 1993; 327–36
   Google Scholar
• Bowyer S L, Ragsdale C G, Sullivan D B. Factor VIII related antigen and childhood rheumatic diseases. J Rheumatol 1989; 16: 1093–7
   PubMed Web of Science ®Google Scholar
• Yazici H, Hekim N, Özbakir F, Yurdakul S, Tüzün Y, Pazarli H, et al. Von Willebrand Factor in Behqet's syndrome. J Rheumatol 1987; 14: 305–6
   PubMed Web of Science ®Google Scholar
• Lau C S, McLaren M, Hanslip J, Kerr M, Belch J JF. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. Ann Rheum Dis 1993; 52: 643–9
   PubMed Web of Science ®Google Scholar
• Mussoni L, Pintucci G, Romano G, Benedetti F D, Massa M, Martini A. Decreased fibrinolytic activity in Juvenile chronic arthritis. Ann Rheum Dis 1990; 49: 973–5
   PubMed Web of Science ®Google Scholar
• Bithell T C. Blood coagulation. Wintrobe's Clinical Hematology, G R Lee, T C Bithell, J Foerster, J W Athens, J N Lukens. Lea and Febiger. 1993; 566–601
   Google Scholar
• Brommer E JP, Dooijewaard G, Dijkmans B AC, Breedveld F C. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992; 51: 965–8
   PubMed Web of Science ®Google Scholar
• Bazzan M, Tamponi G, Gallo E, Stella S, Schinco P C, Panacchia A, et al. Fibrinolytic imbalance in essential throm-bocythemia. Haemostasis 1993; 23: 38–44
   PubMedGoogle Scholar
• Bick R L, Ucar K. Hypercoagulability and thrombosis. Hematol Oncol Clin North Am 1992; 6: 1421–31
   PubMed Web of Science ®Google Scholar
• Bithell T C. Thrombosis and antithrombotic therapy. Wintrobe's Clinical Hematology, G R Lee, T C Bithell, J Foerster, J W Athens, J N Lukens. Lea and Febiger. 1993; 1515–41
   Google Scholar
• International Study Group for Behqet's Disease. Evaluation of diagnostic criteria in Behqet's Disease. Br J Rheumatol 1992; 31: 299–308
   PubMedGoogle Scholar
• Suzuki N, Sakane T, Ueda Y, et al. Abnormal B cell function in patients with Behget's Disease. Arthritis Rheum 1986; 29: 212–19
   PubMed Web of Science ®Google Scholar
• Kushner I. C-reactive protein and the acute phase response. Hospital Practice 1990; 3: 13–28
   Google Scholar
• Schultz D R, Arnold P I. Propertiea of four acute phase proteins. Semin Arthritis Rheum 1990; 20: 129–47
   PubMed Web of Science ®Google Scholar
• Müftüoglu A Ü, Yazici H, Yurdakul S, Tüzün Y, Pazarh H, Güngen G, et al. Relation of C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986; 25: 235–9
   PubMed Web of Science ®Google Scholar
• Tornai I, Harsfalvi J, Boda Z, Udvardy M, Pfliegler G, Rak K. Endothelium releases more von Willebrand factor and Tissue-Type plasminogen Activator upon venous occlusion in patients with liver cirrhosis than in normals. Haemostasis 1993; 23: 58–64
   PubMedGoogle Scholar
• Farrel A J, Williams R B, Stevens C R, Lawrie A S, Cox N L, Blake D R. Exercise induced release of von Willebrand factor. Ann Rheum Dis 1992; 51: 1117–22
   PubMedGoogle Scholar
• Hamilton K K, Ji Z, Rollins S, Stewart B H, Sims P J. Regulatory control of the terminal complement proteins at the surface of human endothelial cells. Blood 1990; 76: 2572–7
   PubMed Web of Science ®Google Scholar
• Blann A D, Wainwright A C, Sheeran T P, Emery P. Venostasis, subclinical vasculitis and von Willebrand factor antigen. Br J Rheumatol 1991; 30: 373–5
   PubMedGoogle Scholar
• James D G. Silk route disease. Postgrad Med J 1986; 62: 151–3
   PubMed Web of Science ®Google Scholar
• Mullaney J, Colium L MT. Ocular vasculitis in Behqet's Disease. Int Ophthalmol 1985; 7: 183–91
   PubMed Web of Science ®Google Scholar
• Chajek T, Aronowski E, Izak G. Decreased fibrinolysis in BehFt's Disease. Thromb Diath Haemorrh 1973; 29: 610–8
   PubMedGoogle Scholar
• Jorizzo J L, Rogers R S. Behqet's disease. J Am Acad Dermatol 1990; 23: 738–42
   PubMedGoogle Scholar
• Byron M A, Allington M J, Chapel H M, Mowat A G, Williams S AC. Indications of vascular endothelial cell dysfunction in systemic lupus erythematosus. Ann Rheum Dis 1987; 46: 741–5
   PubMed Web of Science ®Google Scholar
• Chandler W L, Levy W C, Veith R C, Stratton J R. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion and endurance training. Blood 1993; 81: 3293–302
   PubMed Web of Science ®Google Scholar
• Menache D. Antithrombin III. Semin Hematol 1991; 28: 1–2
   PubMed Web of Science ®Google Scholar
• Pratt C W, Church F C. Antithrombin: structure and function. Semin Hematol 1991; 28: 3–9
   PubMed Web of Science ®Google Scholar
• Bauer K A, Rosenberg R D. Role of antithrombin III as a regulator of in vivo coagulation. Semin Hematol 1991; 28: 10–8
   PubMed Web of Science ®Google Scholar